Healthcare stocks are often viewed by investors as safe-havens during bear markets, so last year's correction in the S&P 500 could be one reason why healthcare companies were some of 2018's top performers. In spite of rising stock market volatility and returns last year, clinical trial results, FDA approvals, and new product launches helped Tandem Diabetes (NASDAQ: TNDM), Amarin Corp. (NASDAQ: AMRN), Abiomed (NASDAQ: ABMD), and Merck & Co. (NYSE: MRK) deliver envy-inspiring gains for investors last year. Can these top stocks reward shareholders again in 2019?
In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:
● How a game-changing new product sparked a 1,480% return in Tandem Diabetes;
● Why results from a long-awaited trial caused Amarin's shares to soar 239%;
● What caused Abiomed's shares to skyrocket 74%;
● And, the one blockbuster drug behind Merck's 36% rally higher in 2018.
Subscribe to The Motley Fool's YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: